FDA Approves Atacicept for IgA Nephropathy - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.

  • By

  • Kathryn Wighton

  • July 7, 2026

  • 3 min

Share

Objective:

To report the FDA's accelerated approval of atacicept for reducing proteinuria in adults with primary IgA nephropathy.

Approach:
  • Clinical Trial Design: The efficacy and safety of atacicept were evaluated in a randomized, double-blind, placebo-controlled clinical trial (NCT04716231) involving adults with biopsy-confirmed primary IgA nephropathy.
  • Treatment Administration: Patients received atacicept 150 mg subcutaneously once weekly or placebo, with the primary endpoint being the change in proteinuria after 9 months.
Key Findings:
  • Atacicept resulted in a 46% reduction in proteinuria at 9 months compared to placebo.
  • Atacicept is the first approved therapy targeting both B-cell activating factor and A Proliferation Inducing Ligand.
Interpretation:

Limitations:
  • The risk of infections associated with atacicept use requires careful patient monitoring.
Conclusion:

Atacicept has received accelerated approval for IgA nephropathy, with ongoing trials needed to confirm long-term benefits.

Sources:

Original Source(s)

FDA Approves Atacicept for IgA Nephropathy

  • by Kathryn Wighton

  • July 7, 2026

Related Content

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.